| abstract |
The invention concerns chimeric monoclonal antibodies, humanized or human produced in selected cell lines, said antibodies exhibiting high affinity for the CD16 receptor of effector cells of the immune system and hence capable of inducing high ADCC, but also the property of inducing cytokine and interleukin secretion, in particular IFN gamma , which can enhance the ADCC activity of effector cells and hence be used for treating cancers and infections by pathogenic agents. |